What the label lists and what reports show
Naratriptan side effects
Naratriptan's FDA label: “Most common adverse reactions (≥2% and >placebo) were paresthesias, nausea, dizziness, drowsiness, malaise/fatigue, and throat/neck symptoms.” FAERS holds 1,369 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is nausea (107 reports).
- Generic listed
Check it at the source: the naratriptan FDA label on DailyMed (effective October 30, 2025, Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.); the FDA FAERS public dashboard.
What does the patient leaflet say about side effects?
From the patient leaflet: What are the possible side effects of naratriptan tablets?Naratriptan tablets may cause serious side effects. See "What is the most important information I should know about naratriptan tablets?" These serious side effects include: • changes in color or sensation in your fingers and toes (Raynaud's syndrome) • stomach and intestinal problems (gastrointestinal and colonic ischemic events). Symptoms of gastrointestinal and colonic ischemic events include: • sudden or severe stomach pain • stomach pain after meals • weight loss • nausea or vomiting • constipation or diarrhea • bloody diarrhea • fever • problems with blood circulation to your legs and feet (peripheral vascular ischemia). […]
Source: FDA drug label, Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., effective October 30, 2025 (SPL set 41c29652-32f8-48dc-9038-0e2195aa2084), via openFDA; the full label on DailyMed
What does the label list?
From the label: adverse reactionsMost common adverse reactions (≥2% and >placebo) were paresthesias, nausea, dizziness, drowsiness, malaise/fatigue, and throat/neck symptoms.
Table 1: Adverse Reactions Reported by at Least 2% of Patients Treated with Naratriptan and at a Frequency Greater Than Placebo
This table is printed in the Naratriptan label published by Hikma Pharmaceuticals USA Inc. of March 3, 2023; the label quoted above does not print one.
| Adverse Reaction | Naratriptan 1 mg (n=627) | Naratriptan 2.5 mg (n=627) | Placebo (n=498) |
|---|---|---|---|
| Atypical Sensation Paresthesias (all types) | 2 | 4 | 1 |
| Gastrointestinal Nausea | 6 | 7 | 5 |
| Neurological Dizziness Drowsiness Malaise/Fatigue | 4 | 7 | 3 |
| Pain and Pressure Sensation Throat/Neck Symptoms | 2 | 4 | 2 |
Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.
From the label: adverse reactions, continuedThe following adverse reactions are discussed in more detail in other sections of the prescribing information: Myocardial ischemia, myocardial infarction, and Prinzmetal's angina [see Warnings and Precautions (5.1 ) ] Arrhythmias [see Warnings and Precautions (5.2) ] Chest, throat, neck, and/or jaw pain/tightness/pressure [see Warnings and Precautions (5.3) ] Cerebrovascular events [see Warnings and Precautions (5.4) ] Other vasospasm reactions [s ee Warnings and Precautions (5.5) ] Medication overuse headache [see Warnings and Precautions (5.6) ] Serotonin syndrome [see Warnings and Precautions (5.7) ] Increase in blood pressure [see Warnings and Precautions (5.8) ] Hypersensitivity reactions [see Contraindications (4), Warnings and Precautions (5.9) ] Most common adverse reactions (≥2% and >placebo) were paresthesias, nausea, dizziness, drowsiness, malaise/fatigue, and throat/neck symptoms. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. …
Source: FDA drug label, Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., effective October 30, 2025 (SPL set 41c29652-32f8-48dc-9038-0e2195aa2084), via openFDA; the full label on DailyMed
What do FAERS reports show?
1,369 reports list naratriptan among the medicines taken, each a report of something that happened, not proof the medicine caused it; 20 are coded as a death and 278 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 20 reactions below, 8 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.
Reports received each year
The 25 most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms
What next?
- Naratriptan: the full record
- label, generics, price, shortages, recalls
- Report a side effect to the FDA
- MedWatch
- Side effects hub
- the most reported medicines and reactions